Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

GCAR1, en chimært antigenreceptor (CAR) T-celle-terapi for tilbagevendende/refraktære GPNMB-eksprimerende solide tumorer

10. november 2026 opdateret af: Canadian Cancer Trials Group

En fase I-studie af GCAR1, en chimært antigenreceptor (CAR) T-celleterapi for deltagere med udvalgte recidiverende/refraktære GPNMB-eksprimerende solide tumorer

Only enrolling in Canada.

The purpose of this study is to identify the highest dose of GCAR1, a chimeric antigen receptor (CAR-T) cell therapy, that can be tolerated without causing very severe side effects, and to see what effects GCAR1 has on selected cancers

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

GCAR1 is a type of CAR-T cell therapy that is designed to identify a protein (GPNMB) that is present on the cells of certain types of cancer. Laboratory tests have shown that GCAR1 helps the immune system recognize cancer cells and may help slow down cancer growth.

The purpose of this study is to find out what effects the new treatment, GCAR1 has on certain cancers. This study will test increasing doses of GCAR1 in participants with alveolar soft part sarcoma (ASPS), triple negative breast cancer (TNBC), and renal cell carcinoma (RCC) expressing high levels of the GPNMB protein, to establish recommended doses for further testing.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

30

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • Alberta
      • Calgary, Alberta, Canada, T2N 5G2
        • Rekruttering
        • Arthur J.E. Child Comprehensive Cancer Centre
        • Kontakt:
          • Mona Shafey
          • Telefonnummer: 403 944-8047
    • Ontario
      • Ottawa, Ontario, Canada, K1H 8L6
        • Rekruttering
        • Ottawa Hospital Research Institute
        • Kontakt:
          • Natasha Kekre
          • Telefonnummer: 71064 613 737-8899
      • Toronto, Ontario, Canada, M5G 2M9
        • Rekruttering
        • University Health Network
        • Kontakt:
          • Abdulazeez Salawu
          • Telefonnummer: 416 946-4501
    • Quebec
      • Montreal, Quebec, Canada, H4A 3J1
        • Rekruttering
        • The Research Institute of the McGill University
        • Kontakt:
          • Ramy Saleh

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

15 år og ældre (Barn, Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Archival tumour specimen must be positive for GPNMB with high expression by immunohistochemistry (central laboratory testing).

  • Histologically and/or cytologically confirmed diagnosis of one of the following tumours that is advanced/ metastatic/ recurrent or unresectable, for which no curative therapy exists.

  • alveolar soft part sarcoma

  • renal cell carcinoma (excluding clear cell)

  • triple negative breast cancer (ER, PR and HER-2 negative as defined by ASCO/CAP criteria)

  • Must have a formalin fixed paraffin embedded tissue block (from primary or metastatic tumour) available and must have provided informed consent for the release of the block.

  • Presence of radiologically documented disease.

  • Measurable disease as defined by RECIST 1.1.

  • ASPS participants ≥ 15 years of age.

  • TNBC and RCC participants ≥ 18 years of age.

  • ECOG performance status of 0 or 1 or Karnofsky or Lansky > 60.

  • Anticipated life expectancy of ≥ 6 months.

  • Must have received prior systemic therapy as shown below;

  • ASPS - completed all systemic therapy available that has been shown to improve survival (unless contraindicated).

  • TNBC

    1. Progressive disease following at least one line of systemic treatment for metastatic disease which must include an ADC (all participants) and an ICI (participants whose tumours express PD-L1).
    2. ≤3 lines of treatment for metastatic disease.
    3. Must have had at least 1 prior line of cytotoxic chemotherapy for breast cancer, in any setting, which must have included an anthracycline and a taxane (unless contraindicated).
  • RCC - must have progressive disease following at least one line of systemic treatment for metastatic disease that must have included an ICI and a VEGFR targeted agent (unless contraindicated).

  • Participants must have recovered to ≤ grade 1 from all reversible toxicity related to prior therapies.

  • Adequate washout must be followed per protocol.

  • Previous major surgery is permitted ≥21 days prior to enrollment

  • Prior external beam radiation is permitted ≥28 prior to enrollment. Concurrent radiotherapy is not permitted.

  • Adequate hematologic and biochemical parameters.

  • Consent and assent, when applicable, must be appropriately obtained in accordance with applicable local and regulatory requirements. Each participant or their parent/ legal guardian (if applicable) must sign a consent form prior to screening onto the trial to document their willingness to participate.

  • Fit for leukapheresis and has adequate venous access for cell collection.

  • Must be accessible for treatment and follow up at the participating centre for a minimum of 12 months or for as long as is deemed necessary by the treating physician.

  • Participants of childbearing potential must have agreed to use a highly effective contraceptive method.

Exclusion criteria

  • Participants on active anticancer therapy for other advanced or metastatic malignancies.
  • Concurrent treatment with other anti-cancer therapy
  • Prior therapy with a gene therapy product or any adoptive T cell therapy or prior GPNMB targeting therapy.
  • Live attenuated vaccination administered within 30 days prior to or planned within 30 days after GCAR1 therapy.
  • Primary immunodeficiency or history of severe autoimmune disease (including: Crohn's disease, rheumatoid arthritis, systemic lupus) requiring immunosuppressive agents/ systemic disease modifying agents within 2 years of enrollment.
  • Active or uncontrolled infections or with serious illnesses or medical conditions which would not permit the participant to be managed according to the protocol including but not limited to:
  • Hepatitis B or C virus (HBV or HCV). For participants with previous HBV or HCV infection who are currently on treatment, they are eligible if they have an undetectable viral load via quantitative PCR and/or nucleic acid testing
  • HIV
  • Uncontrolled fungal, bacterial, viral or other infection
  • Current infection with HTLV
  • Tuberculosis
  • Syphilis
  • West Nile Virus
  • Untreated and/or uncontrolled cardiovascular conditions and/or symptomatic cardiac dysfunction (including cardiac ventricular arrhythmias requiring medication, history of 2nd or 3rd degree atrioventricular conduction defects) or unstable angina congestive heart failure or myocardial infarction within the previous year.
  • Known sensitivity or allergy to fludarabine, cyclophosphamide or any of their components, or to GCAR1 or any of its components.
  • Active intracerebral metastases or leptomeningeal disease. Participants who have received definitive treatment, are clinically stable and do not require corticosteroids are eligible to participate in the trial.
  • Pregnant or breastfeeding women.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: GCAR1-infusion

Assigned at enrollment

Assigned at enrollment

Dose escalation

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
To determine the recommended phase II dose (RP2D), defined as the next lower dose below the maximum administered dose, of GPNMB directed CAR T cell therapy
Tidsramme: 3 years

(GCAR1) in participants with selected tumours (alveolar soft part sarcoma, renal cell carcinoma (excluding clear cell), triple negative breast cancer) expressing GPNMB

3 years

Sekundære resultatmål

Resultatmål
Tidsramme
Varighed af svar
Tidsramme: 3 år
3 år
Antal og sværhedsgrad af bivirkninger ved GCAR1 ved brug af CTCAE v5.0
Tidsramme: 3 år
3 år
Samlet responsrate ved brug af RECIST 1.1
Tidsramme: 3 år
3 år

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Studiestol: Mona Shafey, Tom Baker Cancer Centre, Calgary, Alberta, Canada

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

30. august 2026

Primær færdiggørelse (Anslået)

1. december 2028

Studieafslutning (Anslået)

1. september 2033

Datoer for studieregistrering

Først indsendt

9. december 2025

Først indsendt, der opfyldte QC-kriterier

9. december 2025

Først opslået (Faktiske)

22. december 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

12. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. november 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .